Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | recruiting | Phase 1 | 15 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06461988 | Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | recruiting | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| Immuno-PRISM (PRecision Intervention Smoldering Myeloma) |
| recruiting |
| Phase 2 |
| 52 |
| Irene Ghobrial, MDOTHER |
| 1 |
| Jul 16, 2026 |
| clinicaltrials |
| NCT06121843 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 187 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients(STOMP) | recruiting | Phase 1 / Phase 2 | 300 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07649525 | Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level(iFIT) | recruiting | Phase 3 | 1,226 | University of LeedsOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05847569 | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma | recruiting | Phase 2 | 62 | Mayo ClinicOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06340646 | Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) | recruiting | N/A | 990 | Washington University School of MedicineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03308474 | Myeloma Registry Platform (MYRIAM)(MYRIAM) | recruiting | — | 2,200 | iOMEDICO AGINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05650632 | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 210 | AbbVieINDUSTRY | 7 | Jul 13, 2026 | clinicaltrials |
| NCT06644625 | CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study | recruiting | — | 1,665 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06870760 | Pre-malignant States to Hematologic Malignancies in Firefighters | recruiting | — | 300 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06508983 | A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients | recruiting | Phase 3 | 360 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07454187 | To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 40 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06185751 | Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma | recruiting | Phase 1 | 25 | Washington University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | recruiting | Phase 1 | 317 | Regeneron PharmaceuticalsINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT06140524 | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma(LINKER-MGUS1) | recruiting | Phase 2 | 116 | Regeneron PharmaceuticalsINDUSTRY | 7 | Jul 8, 2026 | clinicaltrials |
| NCT07657312 | Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma | recruiting | Phase 2 | 35 | Naresh BummaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689058 | CAR-T in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 10 | Dr. Zaineb AkramOTHER_GOV | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06083922 | A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) | recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06057402 | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)(MagnetisMM15) | recruiting | Phase 4 | 80 | PfizerINDUSTRY | 7 | Jul 1, 2026 | clinicaltrials |
| NCT07292272 | Halt Aging in Survivors of Blood Cancers(HALTAging-1) | recruiting | N/A | 180 | University of NebraskaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07674498 | Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma(PRIME) | recruiting | N/A | 31 | Jules Bordet InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06107738 | Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma(IBEX) | recruiting | Phase 2 | 60 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07559799 | A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)(MARINA) | recruiting | — | 50 | iOMEDICO AGINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05558319 | NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide(GEM21menos65) | recruiting | Phase 3 | 480 | PETHEMA FoundationOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06785415 | Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 37 | Mayo ClinicOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT07663253 | Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients(CHAMPION-01) | recruiting | — | 333 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07319897 | 68Ga-BCMA PET/CT in Multiple Myeloma | recruiting | Phase 2 / Phase 3 | 300 | Peking University First HospitalOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06971848 | Evaluation of Skin Tests in Biotherapy Allergies(ETCABIO) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06636175 | 64Cu-LLP2A for Imaging Hematologic Malignancies | recruiting | Early Phase 1 | 42 | Washington University School of MedicineOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07454382 | A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma | recruiting | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07652138 | Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04483206 | Personalized Autologous Transplant for Multiple Myeloma | recruiting | Phase 1 | 90 | Emory UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05737732 | The Ambient Light Multiple Myeloma Study | recruiting | N/A | 200 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07456605 | Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma | recruiting | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05055063 | A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma | recruiting | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07642362 | Digital Support for Multiple Myeloma Quality of Life(DigiMyQoL) | recruiting | N/A | 108 | CareAcrossINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05561387 | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | recruiting | Phase 3 | 510 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06559033 | Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS(GAMY) | recruiting | — | 300 | University Hospital, RouenOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05776979 | Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients | recruiting | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07018050 | Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | recruiting | Phase 2 | 160 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07200102 | Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03858205 | Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma | recruiting | N/A | 100 | University of Southern CaliforniaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 20, 2026source: clinicaltrials